{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:41:10Z","timestamp":1761896470284,"version":"3.37.3"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0173532","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T19:05:57Z","timestamp":1489086357000},"page":"e0173532","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia"],"prefix":"10.1371","volume":"12","author":[{"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda T.","family":"G\u00f3mez-Casares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Puerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan M.","family":"Alonso-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Collado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1tima","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda L.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan D.","family":"Rodr\u00edguez-Gambarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Mart\u00ednez-Laperche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montse","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolly V.","family":"Fiallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concepci\u00f3n","family":"Ruiz-Nu\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan L.","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6421-7872","authenticated-orcid":true,"given":"Antonio","family":"Jim\u00e9nez-Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Spanish Group of Chronic Myeloid Leukemia (GELMC)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"M Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.02.001","article-title":"Disease-related mortality exceeds treatment-related mortality in patients with chronic myeloid leukemia on second-line or later therapy","volume":"43","author":"E Pearson","year":"2016","journal-title":"Leuk Res"},{"issue":"Suppl 7","key":"ref3","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","article-title":"Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"M Baccarani","year":"2012","journal-title":"Ann Oncol"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"NCP Cross","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","volume":"153","author":"L Foroni","year":"2011","journal-title":"Br J Haematol"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"S Branford","year":"2008","journal-title":"Blood"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/PAT.0b013e32834e4203","article-title":"Establishment of a conversion factor for the Cepheid GeneXpert BCR-ABL assay","volume":"44","author":"M McNiven","year":"2012","journal-title":"Pathology"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.5858\/2007-131-947-QAOTBT","article-title":"Quantitative assessment of the BCR-ABL transcript using the cepheid Xpert BCR-ABL Monitor assay","volume":"131","author":"SD Dufresne","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2010.034389","article-title":"Cartridge-based automated BCR-ABl1 mRNA quantification: Solving the issues of standardization, at what cost?","volume":"96","author":"JM Cayuela","year":"2011","journal-title":"Haematologica"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00277-012-1468-4","article-title":"Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns","volume":"91","author":"CE L\u00f3pez-Jorge","year":"2012","journal-title":"Ann Hematol"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/PAT.0000000000000293","article-title":"A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system","volume":"47","author":"A Enjeti","year":"2015","journal-title":"Pathology"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.leukres.2013.11.016","article-title":"Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response","volume":"38","author":"ME O\u2019Dwyer","year":"2014","journal-title":"Leuk Res"},{"issue":"9","key":"ref13","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"B Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"E Jabbour","year":"2014","journal-title":"Blood"},{"issue":"35","key":"ref15","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"S Branford","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: Results from the 24-month follow-up of the BELA trial","volume":"168","author":"TH Br\u00fcmmendorf","year":"2015","journal-title":"Br J Haematol"},{"issue":"24","key":"ref17","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities","volume":"121","author":"P Jain","year":"2013","journal-title":"Blood"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"TP Hughes","year":"2014","journal-title":"Blood"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.6004\/jnccn.2013.0157","article-title":"Chronic Myelogenous Leukemia, Version 1.2014","volume":"11","author":"S O\u2019Brien","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"M Baccarani","year":"2013","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0173532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T20:21:16Z","timestamp":1658780476000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0173532"}},"subtitle":[],"editor":[{"given":"Matthaios","family":"Speletas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0173532","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}